Saxenda for Children Under 12: Where Is It Approved?

Is Saxenda approved for children younger than 12?

Interest in childhood obesity medicines makes the distinction between prescribing and regulatory authorization particularly relevant. The European indication includes children aged 6 to under 12 who have obesity, defined here as a BMI at or above the 95th percentile, and weigh at least 45 kg. Treatment should begin with a doctor experienced in childhood obesity. [EMA product information](https://www.ema.europa.eu/en/medicines/human/EPAR/saxenda).

In the United States, Saxenda's pediatric indication covers patients aged 12 and older who have obesity and weigh more than 60 kg. Prescribing it to a younger child would fall outside that age indication. European authorization does not change U.S. labeling, and evidence from a clinical trial does not automatically establish an approved use. [U.S. prescribing information, revised February 2026](https://www.novo-pi.com/saxenda.pdf).

What did the liraglutide trial in younger children show?

Saxenda contains liraglutide, a GLP-1 receptor agonist that influences appetite regulation. In SCALE Kids, 82 children aged 6–11 received daily liraglutide or placebo, alongside lifestyle interventions. At 56 weeks, average BMI had fallen 5.8% with liraglutide and risen 1.6% with placebo. The findings were first published online in September 2024. [Fox and colleagues, New England Journal of Medicine](https://www.nejm.org/doi/full/10.1056/NEJMoa2407379).

The distinction between BMI and weight matters during growth. Average body weight increased in both groups, but the increase was smaller with liraglutide. These results demonstrate an effect on weight trajectory; they do not establish prevention of future diabetes or cardiovascular disease. The trial was funded by Novo Nordisk. Its size and duration also limit conclusions about uncommon harms and outcomes extending into adulthood. [SCALE Kids trial](https://www.nejm.org/doi/full/10.1056/NEJMoa2407379).

What risks and additional care should families understand?

Gastrointestinal adverse events occurred in 80% of liraglutide recipients and 54% of placebo recipients in SCALE Kids. Symptoms affecting eating or drinking deserve attention because tolerability can influence whether treatment remains practical. [SCALE Kids safety results](https://www.nejm.org/doi/full/10.1056/NEJMoa2407379).

The U.S. label warns about pancreatitis, gallbladder disease, and dehydration-related kidney injury. It also contraindicates Saxenda for people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. The thyroid warning reflects tumors observed in rodents; whether liraglutide causes these tumors in humans remains unknown. [Saxenda prescribing information](https://www.novo-pi.com/saxenda.pdf).

Medication decisions sit within a broader treatment plan. The U.S. Preventive Services Task Force recommends comprehensive, intensive behavioral interventions for children aged 6 and older with high BMI. Programs providing at least 26 contact hours have demonstrated benefit and commonly involve children and caregivers, nutrition education, physical activity, and practical behavior-change support. Access to this care matters regardless of medication eligibility. [USPSTF recommendation](https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/obesity-in-children-and-adolescents-screening).